Skip to content
DataLookout
Menu

NCT07935564

A Study to Assess the Adverse Events and How Oral ABBV-1606 Moves Through the Body of Healthy Adult Participants.

StatusNot Yet Recruiting
PhasePhase 1
SponsorAbbVie
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Number of Participants Experiencing Adverse Events
Timeframe: Up to approximately 35 days
Maximum observed plasma concentration (Cmax) of ABBV-1606
Timeframe: Up to approximately 5 days
Time to maximum observed plasma concentration (Cmax) (Tmax) of ABBV-1606
Timeframe: Up to approximately 5 days
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCt) of ABBV-1606
Timeframe: Up to approximately 5 days
Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of ABBV-1606
Timeframe: Up to approximately 5 days
Apparent terminal phase elimination constant (β) of ABBV-1606
Timeframe: Up to approximately 5 days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-1606
Timeframe: Up to approximately 5 days
Apparent clearance (CL/F) of ABBV-1606
Timeframe: Up to approximately 5 days
Apparent volume of distribution (Vz/F) of ABBV-1606
Timeframe: Up to approximately 5 days
Dose Normalized Cmax of ABBV-1606
Timeframe: Up to approximately 5 days
Dose Normalized AUC of ABBV-1606
Timeframe: Up to approximately 5 days

Arms and interventions

ABBV-1606 or Placebo Group 1Experimental

Participants will receive a single oral dose of ABBV-1606 or placebo group 1 on day 1.

ABBV-1606 or Placebo Group 2Experimental

Participants will receive a single oral dose of ABBV-1606 or placebo group 2 on day 1.

ABBV-1606 or Placebo Group 3Experimental

Participants will receive a single oral dose of ABBV-1606 or placebo group 3 on day 1.

ABBV-1606 or Placebo Group 4Experimental

Participants will receive a single oral dose of ABBV-1606 or placebo group 4 on day 1.

ABBV-1606 or Placebo Group 5Experimental

Participants will receive a single oral dose of ABBV-1606 or placebo group 5 on day 1.

Drugs: ABBV-1606, Placebo

Sites

1 site in 1 country

  • Acpru /Id# 277795Grayslake, Illinois, United States